Two major challenges in breast cancer treatment are therapeutic resistance and metastatic progression. A major barrier to efficient development of cancer therapeutics is the availability of in vitro preclinical models that accurately reflect the in vivo drug response along with the spatial heterogeneity of each tumor. MISO chip PDX-MDT is an innovative preclinical platform that enables identification of personalized therapy and omics-based biomarker discovery using patient-derived tumor tissue.
As a proof-of-concept, we will validate that PDX-MDT recapitulate in vivo drug response and transcriptomic profiles and demonstrate that PDXMDT can be used as a tumor avatar to predict treatment response, with the potential to guide treatment decisions for patients in real time. We believe that our PDX-MDT platform has the potential to catalyse the next great leap forward in treatment options for metastatic breast cancer patients.
Genome Centre: Génome Québec
User:
| Jean-Luc | Balzer | MISO Chip Inc |